News from neuroderm ltd A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Nov 03, 2014, 07:21 ET NeuroDerm Announces Launch of Initial Public Offering

NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced the launch of its ...


Oct 29, 2014, 03:00 ET NeuroDerm Announces Positive Topline Results of Phase II, Placebo-Controlled Study of Continuous, Subcutaneously Delivered Levodopa/Carbidopa (ND0612L) in Patients with Moderate to Severe Parkinson's Disease

Company also reports encouraging partial results from Phase IIa study of continuous, subcutaneously delivered high-dose liquid levodopa/carbidopa...


Oct 23, 2014, 07:00 ET NeuroDerm Announces Presentation of ND0612L Top-line Phase II Results and ND0612H Preliminary Interim Phase IIa Results at the 2014 Parkinson's Disease Therapeutics Conference

NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that top-line...


Sep 15, 2014, 05:03 ET NeuroDerm Ltd. Files Registration Statement for Proposed Initial Public Offering

NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that it has filed ...


Sep 03, 2014, 10:32 ET NeuroDerm Announces Start of Phase 2a Study of Continuous Subcutaneous Liquid Levodopa/Carbidopa Administration for Patients with Severe Parkinson's Disease

NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that the first...


Aug 21, 2014, 02:10 ET NeuroDerm Secures $16 Million Financing Round

NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that it has...


Aug 04, 2014, 08:00 ET NeuroDerm Announces Eligibility for European Union Centralized Procedure for ND0612H, a Novel Treatment for Advanced Parkinson's Disease

NeuroDerm Ltd. today announced that the European Medicines Agency (EMA) has deemed ND0612H, its product candidate offering continuous delivery of...


Mar 11, 2014, 07:30 ET NeuroDerm Announces Enrollment in a Second Phase 2 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinson's Disease

NeuroDerm, Ltd. announced today that enrollment of patients is ongoing in its second Phase II clinical trial of ND0612, a novel drug formulation for...


Jun 19, 2013, 08:03 ET NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease

NeuroDerm, Ltd. today announced that results from a phase I study in volunteers, and preliminary results from a phase IIA study in advanced...


Jun 13, 2013, 08:16 ET NeuroDerm Announces Presentation of ND0612 Phase 1 and Phase 2 Results at the 2013 International Congress of Parkinson's Disease and Movement Disorders

NeuroDerm, Ltd. today announced that abstracts reporting results from a phase I study in healthy volunteers, and preliminary results from a phase IIA ...


Jun 03, 2013, 06:17 ET NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development of ND0612 for Parkinson's Disease

NeuroDerm, Ltd. was informed today that it was awarded, for the second time, a grant of $1M by The Michael J. Fox Foundation for Parkinson's Research ...


May 31, 2013, 10:53 ET NeuroDerm to Present at the Jefferies 2013 Global Healthcare Conference in New York City

NeuroDerm, Ltd. announced today that Oded Lieberman, PhD MBA, the company's Chief Executive Officer, will present at the Jefferies 2013 Global...


Apr 15, 2013, 09:25 ET NeuroDerm Announces Enrollment in a Phase 2 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinson's Disease

NeuroDerm, Ltd. announced today that enrollment of patients is ongoing in its Phase IIa clinical trial of ND0612, a novel drug formulation for the...


Nov 20, 2012, 07:00 ET NeuroDerm Announces Enrollment in a Phase 1 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinson's Disease

NeuroDerm, Ltd. announced today that enrollment of healthy subjects is ongoing in its Phase I clinical trial of ND0612, a novel drug formulation for...


Mar 09, 2011, 01:59 ET NeuroDerm Initiates Phase 2 Study of ND0611 Dermal Patch in Patients With Parkinson's Disease

NeuroDerm, Ltd. announced today the enrollment of the first group of patients in its Phase I/II clinical trial of ND0611, a new patch for the...


Nov 09, 2010, 12:02 ET NeuroDerm Initiates Phase 2 Study of ND0801 in Patients with ADD/ADHD

NeuroDerm, Ltd. announced today that patient enrollment has begun in a Phase 2a clinical study of ND0801, a new product for the treatment of...


Oct 06, 2010, 08:45 ET NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development of a New Dermal Patch for Parkinson's Disease

NeuroDerm, Ltd. was informed today that it was awarded a grant of $1M by The Michael J. Fox Foundation for Parkinson's Research. These funds will...


Sep 28, 2010, 07:58 ET NeuroDerm Presents at the 14th European Federation of Neurological Societies Meeting and the 2nd World Parkinson's Congress

NeuroDerm, Ltd. announce today that a platform presentation highlighting the company's new dermal patch for the treatment of Parkinson's disease,...


Jun 01, 2010, 06:59 ET NeuroDerm Successfully Completes Enrollment and Dosing in a Phase 1 Clinical Study of ND0611 Dermal Patch for Parkinson's Disease

NeuroDerm, Ltd. announced today the successful enrollment and dosing in its Phase I clinical trial of ND0611. ND0611, a proprietary drug formula...